Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection
Brief Summary: The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: ANA598 200 mg bid or placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: ANA598 400 mg bid or placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: ANA598 800 mg bid or placebo | Intervention Type: DRUG; Name: ANA598 200 mg bid or placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: ANA598 400 mg bid or placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: ANA598 800 mg bid or placebo; Assigned to Arm(s): Cohort 3
B: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)
C: Arm Label: BI 207127 low dose + SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 low dose + SOC | Arm Label: BI 207127 middle dose +SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 middle dose +SOC | Arm Label: BI 207127 high dose+SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 high dose+SOC | Arm Label: Placebo + SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 middle dose +SOC; Assigned to Arm(s): BI 207127 middle dose +SOC | Intervention Type: DRUG; Name: BI 207127 high dose+SOC; Assigned to Arm(s): BI 207127 high dose+SOC | Intervention Type: DRUG; Name: Placebo + SOC; Assigned to Arm(s): Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 low dose + SOC; Assigned to Arm(s): BI 207127 low dose + SOC
D: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A